447 related articles for article (PubMed ID: 23855716)
1. Polymorphisms in CYP2D6 may predict methamphetamine related heart failure.
Sutter ME; Gaedigk A; Albertson TE; Southard J; Owen KP; Mills LD; Diercks DB
Clin Toxicol (Phila); 2013 Aug; 51(7):540-4. PubMed ID: 23855716
[TBL] [Abstract][Full Text] [Related]
2. Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence.
Otani K; Ujike H; Sakai A; Okahisa Y; Kotaka T; Inada T; Harano M; Komiyama T; Hori T; Yamada M; Sekine Y; Iwata N; Iyo M; Sora I; Ozaki N; Kuroda S
Neurosci Lett; 2008 Mar; 434(1):88-92. PubMed ID: 18280655
[TBL] [Abstract][Full Text] [Related]
3. Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure.
Nishii M; Inomata T; Takehana H; Naruke T; Yanagisawa T; Moriguchi M; Takeda S; Izumi T
J Am Coll Cardiol; 2008 Jun; 51(24):2329-35. PubMed ID: 18549918
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 genotype may moderate measures of brain structure in methamphetamine users.
Dean AC; Nurmi EL; Morales AM; Cho AK; Seaman LC; London ED
Addict Biol; 2021 May; 26(3):e12950. PubMed ID: 32767519
[TBL] [Abstract][Full Text] [Related]
5. Clinical and prognostic value of Duke's Activity Status Index along with plasma B-type natriuretic peptide levels in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Parissis JT; Nikolaou M; Birmpa D; Farmakis D; Paraskevaidis I; Bistola V; Katsoulas T; Filippatos G; Kremastinos DT
Am J Cardiol; 2009 Jan; 103(1):73-5. PubMed ID: 19101233
[TBL] [Abstract][Full Text] [Related]
6. The association of methamphetamine use and cardiomyopathy in young patients.
Yeo KK; Wijetunga M; Ito H; Efird JT; Tay K; Seto TB; Alimineti K; Kimata C; Schatz IJ
Am J Med; 2007 Feb; 120(2):165-71. PubMed ID: 17275458
[TBL] [Abstract][Full Text] [Related]
7. Determination of amphetamine, methamphetamine, and hydroxyamphetamine derivatives in urine by gas chromatography-mass spectrometry and its relation to CYP2D6 phenotype of drug users.
Miranda-G E; Sordo M; Salazar AM; Contreras C; Bautista L; Rojas García AE; Ostrosky-Wegman P
J Anal Toxicol; 2007; 31(1):31-6. PubMed ID: 17389081
[TBL] [Abstract][Full Text] [Related]
8. Clinical Characteristics, Histopathological Features, and Clinical Outcome of Methamphetamine-Associated Cardiomyopathy.
Schürer S; Klingel K; Sandri M; Majunke N; Besler C; Kandolf R; Lurz P; Luck M; Hertel P; Schuler G; Linke A; Mangner N
JACC Heart Fail; 2017 Jun; 5(6):435-445. PubMed ID: 28571597
[TBL] [Abstract][Full Text] [Related]
9. Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up.
Vrtovec B; Poglajen G; Lezaic L; Sever M; Domanovic D; Cernelc P; Socan A; Schrepfer S; Torre-Amione G; Haddad F; Wu JC
Circ Res; 2013 Jan; 112(1):165-73. PubMed ID: 23065358
[TBL] [Abstract][Full Text] [Related]
10. Reduced right ventricular ejection fraction as a marker for idiopathic dilated cardiomyopathy compared with ischemic left ventricular dysfunction.
La Vecchia L; Zanolla L; Varotto L; Bonanno C; Spadaro GL; Ometto R; Fontanelli A
Am Heart J; 2001 Jul; 142(1):181-9. PubMed ID: 11431676
[TBL] [Abstract][Full Text] [Related]
11. Methamphetamine use and heart failure: Prevalence, risk factors, and predictors.
Richards JR; Harms BN; Kelly A; Turnipseed SD
Am J Emerg Med; 2018 Aug; 36(8):1423-1428. PubMed ID: 29307766
[TBL] [Abstract][Full Text] [Related]
12. A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy.
Herrmann S; Schmidt-Petersen K; Pfeifer J; Perrot A; Bit-Avragim N; Eichhorn C; Dietz R; Kreutz R; Paul M; Osterziel KJ
Eur Heart J; 2001 Oct; 22(20):1948-53. PubMed ID: 11601839
[TBL] [Abstract][Full Text] [Related]
13. BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial.
Auerbach SR; Richmond ME; Lamour JM; Blume ED; Addonizio LJ; Shaddy RE; Mahony L; Pahl E; Hsu DT
Circ Heart Fail; 2010 Sep; 3(5):606-11. PubMed ID: 20573993
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
15. Methamphetamine use and dental disease: results of a pilot study.
Cretzmeyer M; Walker J; Hall JA; Arndt S
J Dent Child (Chic); 2007; 74(2):85-92. PubMed ID: 18477425
[TBL] [Abstract][Full Text] [Related]
16. Edema index established by a segmental multifrequency bioelectrical impedance analysis provides prognostic value in acute heart failure.
Liu MH; Wang CH; Huang YY; Tung TH; Lee CM; Yang NI; Liu PC; Cherng WJ
J Cardiovasc Med (Hagerstown); 2012 May; 13(5):299-306. PubMed ID: 22367574
[TBL] [Abstract][Full Text] [Related]
17. Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure.
Fujimoto N; Onishi K; Sato A; Terasaki F; Tsukada B; Nozato T; Yamada T; Imanaka-Yoshida K; Yoshida T; Ito M; Hiroe M
J Card Fail; 2009 Dec; 15(10):898-905. PubMed ID: 19944367
[TBL] [Abstract][Full Text] [Related]
18. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study.
McKetin R; Lubman DI; Baker AL; Dawe S; Ali RL
JAMA Psychiatry; 2013 Mar; 70(3):319-24. PubMed ID: 23303471
[TBL] [Abstract][Full Text] [Related]
19. A comparison of echocardiographic findings in young adults with cardiomyopathy: with and without a history of methamphetamine abuse.
Ito H; Yeo KK; Wijetunga M; Seto TB; Tay K; Schatz IJ
Clin Cardiol; 2009 Jun; 32(6):E18-22. PubMed ID: 19330818
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L
Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
